A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public. Quantinuum was created in 2021 when industrial manufacturing juggernaut Honeywell spun off its quantum computing hardware business and merged it with a U.K.-based software firm. The resulting entity now has a global workforce of around 700 employees and touts itself as the “world’s largest integrated quantum company.” The quantum computing company has yet to disclose how many shares it is planning to offer—or at what price—but expects to list its stock on the Nasdaq under the ticker “QNT.” Quantum computing is based on the principles of quantum physics, which describes the behavior of atoms and particles. Unlike a traditional computer, whose CPU performs calculations using bits that have a value of 0 or 1, quantum computers store information in so-called quantum bits, or qubits, which can simultaneously be both 0 and 1 as well as an infinite number of states in between. In principle, this means they could solve problems far beyond the reach of today’s traditional supercomputers. After steadily growing in recent years, venture capital investment in quantum-focused companies exploded in 2025. In fact, last year saw $3.8 billion in VC deal activity in the sector, according to PitchBook data shared with Fierce Biotech, with another $581 million landing within the first two months of 2026 alone. But quantum companies can burn through money fast. While Quantinuum entered April with $677 million in cash and equivalents, a net loss of $136.6 million for the first three months of the year alone means it’s no surprise the company is looking for a fresh infusion of funds. Still, some Big Pharmas have been keen to buy a ticket on the quantum train. That includes Amgen, which has collaborated with Quantinuum to explore how using